Clinical trials in leukemia and lymphoma have provided suggestive evidence that immunotherapy contributes to the overall management of these neoplasms. Not all disease categories nor every patient within a category has benefited from the specific immunotherapy they have received. In fact, there is certain evidence that overstimulation as well as inadequate stimulation may be harmful. Advances in knowledge of the biologic importance of general and specific immunocompetence should lead to a more rational use of immunotherapeutic agents.
|Original language||English (US)|
|Number of pages||23|
|Journal||Seminars in hematology|
|State||Published - Dec 1 1978|
ASJC Scopus subject areas